OPTN / OptiNose, Inc. (OPTN) Q3 2022 Earnings Call Transcript

OptiNose (OPTN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the s more_horizontal

YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat more_horizontal

On August 10, OptiNose, one of the leaders in the global chronic rhinosinusitis market, will publish its financial results for the 2nd quarter of 2023 more_horizontal

YARDLEY, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat ( more_horizontal

OptiNose Inc. (NASDAQ:OPTN ) Q1 2023 Results Conference Call May 11, 2023 8:00 AM ET Company Participants Jonathan Neely - VP of IR and Business Opera more_horizontal

OptiNose (OPTN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0. more_horizontal

Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held May 11, 2023, at 8:00 a.m. Easte more_horizontal

YARDLEY, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat more_horizontal